Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3066145 | Journal of Neuroimmunology | 2006 | 7 Pages |
Abstract
This study aimed at investigating if selective ex vivo immune deviation of myelin-specific cytokine secretion towards Th2 is possible in blood cells from patients with multiple sclerosis (MS). Interleukin (IL)-4 (Th2) and interferon-γ (Th1) secreting cells were recorded by ELISPOT in 13 MS patients. Deviation was successful in 10 patients. Interleukin-4 alone was most effective in inducing myelin-specific immune deviation in MS patients whereas IL-1 or IL-15 in combination with IL-4 did not improve the results. Further studies and improvements are needed before ex vivo immune deviation can be considered a potential treatment in patients with MS.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
E. Hallin, J. Mellergård, M. Vrethem, J. Ernerudh, C. Ekerfelt,